Publication: Associations of the srebf2 gene and insig2 polymorphisms with obesity and dyslipidemia in thai psychotic disorder patients treated with risperidone
Issued Date
2021-10-01
Resource Type
ISSN
20754426
Other identifier(s)
2-s2.0-85115883855
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Personalized Medicine. Vol.11, No.10 (2021)
Suggested Citation
Natchaya Vanwong, Chonlaphat Sukasem, Weerapon Unaharassamee, Napa Jiratjintana, Chalitpon Na Nakorn, Yaowaluck Hongkaew, Apichaya Puangpetch Associations of the srebf2 gene and insig2 polymorphisms with obesity and dyslipidemia in thai psychotic disorder patients treated with risperidone. Journal of Personalized Medicine. Vol.11, No.10 (2021). doi:10.3390/jpm11100943 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/77810
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Associations of the srebf2 gene and insig2 polymorphisms with obesity and dyslipidemia in thai psychotic disorder patients treated with risperidone
Abstract
Background: Patients with psychotic disorders who receive atypical antipsychotic drugs often develop metabolic abnormalities. The sterol regulatory element-binding factor 2 (SREBF2) gene and insulin-induced gene (INSIG) have important roles in lipid metabolism. A previous study indicated that risperidone stimulated both lipogenesis and cholesterogenesis through activation of SREBP2 expression and inhibition of INSIG2. The SREBF2 gene and INSIG2 polymorphisms have been reported to be associated with metabolic abnormalities. Objective: To investigate the association of the SREBF2 gene (rs1052717, rs2267439, and rs2267443) and INSIG2 (rs7566605, rs11123469, and rs17587100) polymorphisms and the presence of obesity and dyslipidemia in Thai psychotic disorder patients treated with risperidone. Methods: All 113 psychiatric patients using risperidone were evaluated for their lipid profile and screened for obesity criteria. We genotyped the SREBF2 gene and INSIG2 polymorphisms using TaqMan real-time polymerase chain reaction. Results: None of the studied SREBF2 gene and INSIG2 SNPs were associated with obesity in Thai psychotic disorder patients receiving risperidone. Nonetheless, the SREBF2 rs2267443 (G/A) A-allele carriers were at a higher risk for hypertriglyceridemia, whereas the INSIG2 rs11123469 (T/C) C-allele carriers had a lower risk for hypertriglyceridemia, after being adjusted for clinical characteristics using multiple logistic regression. Conclusions: Our findings suggest that the SREBF2 gene rs2267443 (G/A) and the INSIG2 rs11123469 (T/C) polymorphisms are associated with dyslipidemia in Thai psychotic disorder patients treated with risperidone. Further studies with prospective designs and larger patient groups are needed.